公开(公告)号：US20150202277A1

公开(公告)日：2015-07-23

申请号：US14420229

申请日：2013-08-29

Applicant: NOVARTIS AG

Inventor： Fabio Bagnoli ,  Simone Bufali ,  Simona Cianetti ,  Anna Coslovi ,  Guido Grandi ,  Mikkel Nissum ,  Michele Pallaoro ,  Silvana Savino ,  Michele Sotgiu

IPC: A61K39/085 ,  A61K39/39

CPC classification number: A61K39/085 ,  A61K39/39 ,  A61K2039/55511 ,  A61K2039/70 ,  C07K14/3156

Abstract: Elimination of disulphide bond formation of cysteine-containing S.aureus antigens enhances antigen stability. The invention provides a composition comprising variant forms of cysteine-containing S.aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.

Abstract translation: 消除含半胱氨酸的金黄色葡萄球菌抗原的二硫键形成增强了抗原的稳定性。 本发明提供包含替代，删除或修饰半胱氨酸残基的点突变的含半胱氨酸的金黄色葡萄球菌抗原的变体形式的组合物。

公开(公告)号：US20150132339A1

公开(公告)日：2015-05-14

申请号：US14381090

申请日：2013-03-07

Applicant: NOVARTIS AG

Inventor： Simone Bufali ,  Paolo Costantino ,  Michele Pallaoro ,  Derek O'hagan ,  Rino Rappuoli ,  Manmohan Singh

IPC: A61K39/09 ,  A61K33/08 ,  A61K31/4745 ,  A61K39/39

CPC classification number: A61K39/092 ,  A61K31/4375 ,  A61K31/4745 ,  A61K33/06 ,  A61K33/08 ,  A61K39/39 ,  A61K45/06 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/6037 ,  A61K2300/00

Abstract: The efficacy of S. pneumoniae vaccines can be enhanced by adjuvanting S. pneumoniae saccharide and/or protein antigens with a mixture of a TLR agonist (preferably a TLR7 agonist) and an insoluble metal salt (preferably an aluminium salt). The TLR agonist is typically adsorbed to the metal salt. The S. pneumoniae antigen can also be adsorbed to the metal salt.

Abstract translation: 通过用TLR激动剂（优选TLR7激动剂）和不溶性金属盐（优选铝盐）的混合物佐剂肺炎链球菌糖和/或蛋白质抗原来增强肺炎链球菌疫苗的功效。 TLR激动剂通常被吸附到金属盐上。 肺炎链球菌抗原也可以被吸附到金属盐上。

公开(公告)号：US20150203543A1

公开(公告)日：2015-07-23

申请号：US14420834

申请日：2013-08-29

Applicant: NOVARTIS AG

Inventor： Fabio Bagnoli ,  Fabiana Falugi ,  Guido Grandi ,  Massimo Mariani ,  Mikkel Nissum ,  Michele Pallaoro ,  Silvana Savino

IPC: C07K14/31 ,  A61K39/085

CPC classification number: C07K14/31 ,  A61K39/085 ,  A61K2039/55505

Abstract: Elimination of disulphide bond formation of cysteine-containing S. aureus antigens enhances antigen stability. The invention provides variant forms of cysteine-containing S. aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.

公开(公告)号：US20150203542A1

公开(公告)日：2015-07-23

申请号：US14420831

申请日：2013-08-29

Applicant: NOVARTIS AG

Inventor： Fabio Bagnoli ,  Fabiana Falugi ,  Guido Grandi ,  Massimo Mariani ,  Mikkel Nissum ,  Michele Pallaoro ,  Silvana Savino

IPC: C07K14/31

CPC classification number: C07K14/31 ,  A61K39/085 ,  A61K2039/55505

Abstract: Elimination of disulphide bond formation of cysteine-containing S. aureus antigens enhances antigen stability. The invention provides variant forms of cysteine-containing S. aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.

Abstract translation: 含有半胱氨酸的金黄色葡萄球菌抗原的二硫键形成的消除增强了抗原的稳定性。 本发明提供具有替代，删除或修饰半胱氨酸残基的点突变的含半胱氨酸的金黄色葡萄球菌抗原的变体形式。

公开(公告)号：US20150191513A1

公开(公告)日：2015-07-09

申请号：US14420937

申请日：2013-08-29

Applicant: NOVARTIS AG

Inventor： Fabio Bagnoli ,  Matthew Bottomley ,  Guido Grandi ,  Mikkel Nissum ,  Michele Pallaoro ,  Silvana Savino

IPC: C07K14/31 ,  A61K39/085

CPC classification number: C07K14/31 ,  A61K39/085 ,  A61K2039/55505

Abstract: Elimination of disulphide bond formation of cysteine-containing S. aureus antigens enhances antigen stability. The invention provides variant forms of cysteine-containing S. aureus antigen with a point mutation that replaces, deletes or modifies the cysteine residue.